 |
emricasan |
|---|---|
| Trade Name | |
| Orphan Indication | Liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease |
| USA Market Approval | USA |
| USA Designation Date | 2013-11-20 00:00:00 |
| Sponsor | Conatus Pharmaceuticals Inc.;16745 W. Bernardo Drive, Suite 200;San Diego, California, 92127 |
